Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Alterations of serum creatine kinase isoenzymes were observed in five cases of prostatic carcinoma. Creatine kinase isoenzyme BB was found in the serum of two of three cases with metastases. Its presence in serum does not seem to be related to acid phosphatase activity but seems associated with extension of the tumor to other tissues. Preliminary studies on effusions from patients with malignant and non-malignant prostates showed that CK-BB was detectable only in cytology positive effusions. This finding suggests that CK-BB may be a tumor product rather than a result of a host response. The observation of CK-BB in a significant percentage of patients (two of three) with metastatic carcinoma of the prostate is of interest and suggests that CK-BB isoenzymes may have some predictive value in following patients with malignant disease.
 ...
PMID:The significance of creatine kinase (CKBB) in metastatic cancer of the prostate. 48 95

This is a case of carcinoma of the gallbladder, which clinically, chemically, and radiographically simulated metastatic prostate cancer. Other causes of elevated serum and bone marrow acid phosphatase and axial skeletal osteoblastic metastases are reviewed.
 ...
PMID:Carcinoma of gallbladder simulating metastatic prostatic cancer. 51 14

Despite the high frequency of skeletal metastases from cancer of the prostate, hypercalcaemia is extremely uncommon in this condition. In two patients with advanced, poorly differentiated metastasizing cancer a fairly uniform clinical picture developed, with anaemia, leukocytosis, increased serum creatinine, thrombocytopenia, elevated alkaline and acid phosphatase levels and symptoms secondary to hypercalcaemia. The development of more effective agents against cancer of the prostate will probably afford longer palliation, but evidently at a risk of severe metabolic disturbances in the preterminal state.
 ...
PMID:Advanced cancer of the prostate combined with hypercalcaemia. 59 76

24-hour urinary hydroxyproline excretion (THP), a marker of bone collagen metabolism, has been measured in 35 patients with carcinoma of the prostate. 21 patients had bone metastases diagnosed by bone scanning (99mTc MDP). All 9 patients with metastases studied before hormonal treatment and the majority of those on treatment had elevated levels. Patients with negative bone scans invariably had normal THP levels. Furthermore, THP reflected the presence of bone metastases more accurately than plasma alkaline or acid phosphatase. Serial THP levels altered predictably with symptomatic response to treatment. These results suggest that THP is more reliable than other markers of the presence and activity of bone metastases in response to treatment and may have been neglected in favour of more elaborate and costly X-ray and isotope investigations.
 ...
PMID:Urine hydroxyproline excretion--a marker of bone metastases in prostatic carcinoma. 59 12

A prospective study was done to evaluate 47 patients with early stage prostatic cancer. Pelvic lymphadenectomy was combined with bone marrow acid phosphatase determination to evaluate early metastatic disease. Thirteen patients (28 per cent) had tumor in the pelvic lymph nodes. In no instance was the bone marrow acid phosphatase elevated to more than the normal value for serum by the substrate used. Combined high grade and stage tumors seemed to have an increased incidence of metastases to pelvic lymph nodes. A surprisingly high incidence of B1 lesions (5 of 21 patients or 24 per cent) had positive lymph nodes. Generally, the nodes were moderately well or well differentiated lesions. The metastases were unilateral, frequently microscopic only and involved 1 or only a few nodes. Pelvic lymphadenectomy seems to have a well defined role in the diagnostic study of early stage prostatic cancer, while bone marrow acid phosphatase determinations were of no value.
 ...
PMID:Early stage prostatic cancer investigated by pelvic lymph node biopsy and bone marrow acid phosphatase. 62 24

Bone marrow acid phosphatase has been reported to be a sensitive indicator of early bony metastasis from adenocarcinoma of the prostate. In order to evaluate this hypothesis, we measured bone marrow acid and alkaline phosphatase, lactic dehydrogenase, and calcium levels in a group of 84 patients with a variety of problems, including 18 with cancer of the prostate. We found that the bone marrow acid and alkaline phosphatase and lactic dehydrogenase were elevated and calcium was depressed in most patients. Among patients with prostate cancer, bone marrow acid phosphatase was not significantly different between those with or without bone metastases. In addition, the patients with prostatic cancer did not have higher levels of bone marrow acid phosphatase than subjects with other malignant and nonmalignant conditions. The level of acid and alkaline phosphatase, lactic dehydrogenase and calcium varied predictably with the aspiration technique used and was independent of sex, disease state or method of chemical determination. Due to this variation, we believe that bone marrow enzyme and calcium levels are of no value in the detection of metastases in patients with prostate cancer.
 ...
PMID:Lack of usefulness of bone marrow enzymes and calcium in staging patients with prostatic cancer. 63 3

To evaluate the reliability of bone marrow acid phosphatase in the staging of prostatic carcinoma we analyzed 50 bone marrow samples collected at random from the hematology service at this hospital. The samples were assayed for acid phosphatase content by a colorimetric method using sodium thymolphthalein monophosphate as a substrate and by 2 immunochemical assays developed at our laboratory (counter immunoelectrophoresis and radioimmunoassay). We found a high percentage (61 per cent) of falsely positive results in patients with various hematological diseases without evidence of prostatic carcinoma by the colorimetric evaluation. All of these patients except 1 had negative immunochemical assay. Until a specific assay for prostatic acid phosphatase is developed for clinical use we caution the use of a single elevation of bone marrow acid phosphatase as a parameter of metastatic disease.
 ...
PMID:Bone marrow acid phosphatase in staging of prostatic cancer: how reliable is it? 66 Jul 63

Three cases of metastatic adenocarcinoma of the male breast from prostatic carcinoma are added to the 15 well-documented cases reported in the literature. These 15 cases had received estrogen therapy for prostatic cancer and gynecomastia developed; 14 had clinically palpable breast nodules containing adenocarcinoma. Our 3 cases also received estrogen therapy but differed in that gynecomastia developed in only 1 patient clinically, and diagnoses were made at autopsy with no clinical symptoms related to breast metastases. Moreover, 1 cases also showed remarkable florid lactation-like changes of the breast almost indistinguishable morphologically from that seen in the female breast during pregnancy. The histopathologic differential diagnosis of metastatic prostatic carcinoma of the breast from primary cancer of the male breast is stressed. Its importance is obvious because of the differences in clinical treatment and prognosis. Microscopically, the differential points consist of duct hypertrophy and periductal fibrosis (gynecomastia), absence of any ductal involvement by carcinoma cells, frequent presence of cancer cells in lymphatics and vascular channels, morphologic similarity between the cancers in the breast and prostate, and finally, the usual presence of acid phosphatase in the tumors of the prostate and breast.
 ...
PMID:Metastatic prostatic adenocarcinoma of male breast. 67 36

The results of radiation therapy of patients with carcinoma of the prostate category T3-4NxMo are compared with those of the hormonal therapy and with those of hormonal therapy combined with external irradiation. The type of first indicators of existing or threatening metastases has been evaluated, their appearance after first treatment and the period between their appearance and the development of clinical metastases have been assessed. These data and perhaps the bone-marrow serum acid phosphatase levels prior to treatment might be helpful in the choice of treatment. As damage due to irradiation has become minimal, radiation therapy should be preferred in all patients prone to cardio-vascular accidents and in healthy men up to about 75 years.
 ...
PMID:Prostatic cancer treated at the Rotterdam radiotherapy institute. 68 74

Bone scanning with 99mTc-Sn-HEDP, radiographic skeletal survey and determination of plasma acid and alkaline phosphatase values were carried out in a consecutive series of 90 untreated patients with carcinoma of the prostate. 99mTc-Sn-HEDP provided satisfactory bone imaging and was convenient in use. The addition of bone scanning to radiographic survey increases the detection rate of skeletal metatases by 16%. Radiography increases the accuracy of bone scanning by identifying false positive scans due to benign disease and false negative scans when there are diffuse symmetrical bony metastases. The plasma phosphatases alone are less accurate staging tests. The acid phosphatase data support the validity of scan positive--X-ray negative findings. Bone scan abnormalities due to secondary deposits usually precede elevation of plasma alkaline phosphatase.
 ...
PMID:Bone scanning and plasma phosphatases in carcinoma of the prostate. 75 55


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>